Agios Historical Balance Sheet

AGIO Stock

USD 34.44 0.75 2.13%

Trend analysis of Agios Pharm balance sheet accounts such as Other Current Liab of 30 M, Total Current Liabilities of 76.2 M or Total Stockholder Equity of 1.6 B provides information on Agios Pharm's total assets, liabilities, and equity, which is the actual value of Agios Pharm to its prevalent stockholders. By breaking down trends over time using Agios Pharm balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Agios Pharm latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Agios Pharm is a good buy for the upcoming year.

Agios Pharm Inventory

29 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

About Agios Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Agios Pharm at a specified time, usually calculated after every quarter, six months, or one year. Agios Pharm Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Agios Pharm and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Agios currently owns. An asset can also be divided into two categories, current and non-current.

Agios Pharm Balance Sheet Chart

At this time, Agios Pharm's Total Liabilities is very stable compared to the past year. As of the 26th of February 2025, Property Plant And Equipment Gross is likely to grow to about 116.6 M, while Other Current Liabilities is likely to drop about 30 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Agios Pharm assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Agios Pharm books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Agios Pharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Agios Pharm are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Agios Pharm's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Total Liabilities is very stable compared to the past year. As of the 26th of February 2025, Property Plant And Equipment Gross is likely to grow to about 116.6 M, while Other Current Liabilities is likely to drop about 30 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	30.4M	43.2M	30.1M	30.0M
Total Assets	1.2B	937.1M	1.7B	1.7B

Other Current Liab Total Assets

Agios Pharm balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.58	0.49	0.98	-0.3	0.64	-0.37	0.19	-0.14	0.61	-0.08	0.94	0.63	0.71	0.84	0.8	0.77	0.88	0.01	0.75	0.72	0.2	0.74	0.88	-0.01	0.8
Other Current Liab	0.58		0.85	0.44	0.36	0.8	0.01	-0.16	-0.85	0.8	0.31	0.41	-0.03	0.18	0.66	0.81	0.91	0.67	0.64	0.73	0.94	0.75	0.58	0.69	0.24	0.83
Total Current Liabilities	0.49	0.85		0.36	0.45	0.5	0.34	-0.38	-0.74	0.85	0.48	0.41	0.09	-0.01	0.48	0.66	0.77	0.53	0.57	0.48	0.8	0.73	0.38	0.52	0.54	0.66
Total Stockholder Equity	0.98	0.44	0.36		-0.46	0.54	-0.41	0.21	0.01	0.51	-0.12	0.94	0.67	0.75	0.8	0.74	0.67	0.85	-0.18	0.66	0.62	0.01	0.69	0.84	-0.08	0.74
Other Liab	-0.3	0.36	0.45	-0.46		0.07	0.48	-0.35	-0.57	0.19	0.37	-0.34	-0.28	-0.44	-0.18	-0.09	0.12	-0.26	0.88	0.08	0.13	0.83	-0.07	-0.2	0.49	-0.09
Property Plant And Equipment Net	0.64	0.8	0.5	0.54	0.07		-0.44	0.36	-0.65	0.63	-0.2	0.48	-0.07	0.35	0.7	0.78	0.85	0.71	0.52	0.84	0.85	0.57	0.61	0.74	-0.22	0.8
Current Deferred Revenue	-0.37	0.01	0.34	-0.41	0.48	-0.44		-0.81	-0.06	0.23	0.77	-0.39	-0.26	-0.47	-0.21	-0.23	-0.22	-0.29	0.16	-0.48	-0.19	0.18	-0.48	-0.28	0.91	-0.23
Net Debt	0.19	-0.16	-0.38	0.21	-0.35	0.36	-0.81		0.14	-0.32	-0.99	0.23	0.17	0.43	-0.03	0.06	-0.01	0.09	-0.07	0.3	0.0	-0.11	0.34	0.1	-0.72	0.06
Retained Earnings	-0.14	-0.85	-0.74	0.01	-0.57	-0.65	-0.06	0.14		-0.6	-0.25	-0.02	0.38	0.22	-0.28	-0.53	-0.69	-0.29	-0.77	-0.48	-0.76	-0.8	-0.31	-0.3	-0.1	-0.55
Accounts Payable	0.61	0.8	0.85	0.51	0.19	0.63	0.23	-0.32	-0.6		0.44	0.53	0.04	0.11	0.68	0.77	0.81	0.65	0.39	0.53	0.82	0.54	0.4	0.65	0.41	0.78
Cash	-0.08	0.31	0.48	-0.12	0.37	-0.2	0.77	-0.99	-0.25	0.44		-0.15	-0.18	-0.38	0.17	0.08	0.16	0.04	0.16	-0.16	0.15	0.21	-0.25	0.04	0.72	0.09
Non Current Assets Total	0.94	0.41	0.41	0.94	-0.34	0.48	-0.39	0.23	-0.02	0.53	-0.15		0.76	0.68	0.65	0.65	0.62	0.7	-0.09	0.6	0.58	0.12	0.66	0.69	-0.07	0.64
Non Currrent Assets Other	0.63	-0.03	0.09	0.67	-0.28	-0.07	-0.26	0.17	0.38	0.04	-0.18	0.76		0.64	0.21	0.2	0.14	0.31	-0.29	0.24	0.08	-0.11	0.49	0.29	0.02	0.18
Other Assets	0.71	0.18	-0.01	0.75	-0.44	0.35	-0.47	0.43	0.22	0.11	-0.38	0.68	0.64		0.51	0.41	0.35	0.57	-0.22	0.51	0.29	-0.11	0.72	0.58	-0.15	0.41
Cash And Short Term Investments	0.84	0.66	0.48	0.8	-0.18	0.7	-0.21	-0.03	-0.28	0.68	0.17	0.65	0.21	0.51		0.86	0.83	0.94	0.14	0.81	0.78	0.23	0.62	0.96	0.07	0.86
Common Stock Total Equity	0.8	0.81	0.66	0.74	-0.09	0.78	-0.23	0.06	-0.53	0.77	0.08	0.65	0.2	0.41	0.86		0.9	0.93	0.25	0.81	0.92	0.36	0.7	0.91	0.04	1.0
Common Stock Shares Outstanding	0.77	0.91	0.77	0.67	0.12	0.85	-0.22	-0.01	-0.69	0.81	0.16	0.62	0.14	0.35	0.83	0.9		0.86	0.46	0.86	0.98	0.58	0.68	0.86	0.05	0.91
Short Term Investments	0.88	0.67	0.53	0.85	-0.26	0.71	-0.29	0.09	-0.29	0.65	0.04	0.7	0.31	0.57	0.94	0.93	0.86		0.07	0.81	0.82	0.18	0.67	0.99	0.02	0.92
Non Current Liabilities Total	0.01	0.64	0.57	-0.18	0.88	0.52	0.16	-0.07	-0.77	0.39	0.16	-0.09	-0.29	-0.22	0.14	0.25	0.46	0.07		0.45	0.48	0.96	0.22	0.15	0.27	0.26
Other Current Assets	0.75	0.73	0.48	0.66	0.08	0.84	-0.48	0.3	-0.48	0.53	-0.16	0.6	0.24	0.51	0.81	0.81	0.86	0.81	0.45		0.82	0.51	0.81	0.85	-0.15	0.8
Other Stockholder Equity	0.72	0.94	0.8	0.62	0.13	0.85	-0.19	0.0	-0.76	0.82	0.15	0.58	0.08	0.29	0.78	0.92	0.98	0.82	0.48	0.82		0.59	0.66	0.81	0.05	0.93
Total Liab	0.2	0.75	0.73	0.01	0.83	0.57	0.18	-0.11	-0.8	0.54	0.21	0.12	-0.11	-0.11	0.23	0.36	0.58	0.18	0.96	0.51	0.59		0.33	0.25	0.34	0.38
Property Plant And Equipment Gross	0.74	0.58	0.38	0.69	-0.07	0.61	-0.48	0.34	-0.31	0.4	-0.25	0.66	0.49	0.72	0.62	0.7	0.68	0.67	0.22	0.81	0.66	0.33		0.68	-0.13	0.7
Total Current Assets	0.88	0.69	0.52	0.84	-0.2	0.74	-0.28	0.1	-0.3	0.65	0.04	0.69	0.29	0.58	0.96	0.91	0.86	0.99	0.15	0.85	0.81	0.25	0.68		0.04	0.9
Short Term Debt	-0.01	0.24	0.54	-0.08	0.49	-0.22	0.91	-0.72	-0.1	0.41	0.72	-0.07	0.02	-0.15	0.07	0.04	0.05	0.02	0.27	-0.15	0.05	0.34	-0.13	0.04		0.04
Common Stock	0.8	0.83	0.66	0.74	-0.09	0.8	-0.23	0.06	-0.55	0.78	0.09	0.64	0.18	0.41	0.86	1.0	0.91	0.92	0.26	0.8	0.93	0.38	0.7	0.9	0.04

Click cells to compare fundamentals

Agios Pharm Account Relationship Matchups

Agios Pharm balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	853.0M	1.4B	1.2B	937.1M	1.7B	1.7B
Other Current Liab	61.9M	32.0M	30.4M	43.2M	30.1M	30.0M
Total Current Liabilities	94.4M	59.8M	62.6M	68.0M	81.2M	76.2M
Total Stockholder Equity	399.5M	1.3B	1.1B	811.0M	1.5B	1.6B
Other Liab	77.4M	50.6M	261.3M	3.3M	3.8M	3.6M
Property Plant And Equipment Net	117.5M	104.2M	88.1M	69.8M	54.6M	53.0M
Net Debt	(22.2M)	(106.0M)	(53.6M)	(16.2M)	(19.3M)	(20.2M)
Retained Earnings	(1.8B)	(238.8M)	(470.6M)	(822.6M)	(148.9M)	(156.4M)
Accounts Payable	17.7M	16.7M	18.6M	9.8M	16.6M	15.4M
Cash	127.4M	203.1M	139.3M	88.2M	76.2M	72.4M
Non Current Assets Total	216.3M	373.5M	405.9M	103.3M	697.6M	732.5M
Non Currrent Assets Other	1.1M	2.9M	4.0M	4.1M	643.0M	675.2M
Cash And Short Term Investments	670.5M	1.3B	1.1B	776.9M	893.7M	662.2M
Common Stock Total Equity	58K	68K	69K	71K	81.7K	49.5K
Common Stock Shares Outstanding	69.0M	60.4M	54.8M	55.7M	57.9M	49.8M
Short Term Investments	445.5M	816.9M	643.9M	688.7M	817.5M	462.0M
Liabilities And Stockholders Equity	853.0M	1.4B	1.2B	937.1M	1.7B	1.7B
Non Current Liabilities Total	359.1M	85.9M	75.3M	58.1M	41.1M	39.0M
Other Current Assets	49.1M	39.8M	39.0M	35.0M	40.2M	23.7M
Other Stockholder Equity	2.2B	1.5B	1.6B	1.6B	1.7B	1.3B
Total Liab	453.5M	145.8M	137.9M	126.1M	122.2M	184.1M
Property Plant And Equipment Gross	117.5M	28.9M	138.2M	122.0M	111.1M	116.6M
Total Current Assets	636.7M	1.1B	832.8M	833.8M	965.6M	609.0M
Accumulated Other Comprehensive Income	105K	(1.2M)	(12.5M)	(441K)	(1.5M)	(1.6M)
Short Term Debt	14.8M	11.2M	13.7M	15.0M	33.6M	27.9M
Common Stock	68K	69K	71K	72K	73K	53.8K
Property Plant Equipment	31.5M	32.3M	28.9M	23.0M	26.4M	21.1M
Net Tangible Assets	640.5M	399.5M	1.3B	1.1B	1.3B	633.1M
Net Receivables	25.4M	4.4M	2.2M	2.8M	4.1M	6.8M
Retained Earnings Total Equity	(1.5B)	(1.8B)	(238.8M)	(470.6M)	(423.5M)	(444.7M)
Capital Surpluse	2.2B	2.2B	2.3B	2.4B	2.7B	1.7B
Inventory	14.7M	16.2M	8.5M	19.1M	27.6M	29.0M
Long Term Investments	97.6M	266.4M	313.9M	29.4M	638.3M	670.2M
Non Current Liabilities Other	359.1M	85.9M	3.3M	1.2M	880K	836K
Net Invested Capital	399.5M	1.3B	1.1B	811.0M	1.5B	941.6M
Net Working Capital	542.3M	1.0B	770.1M	765.9M	884.4M	736.5M
Capital Stock	68K	69K	71K	72K	73K	75.7K

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

0.64	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.6	GANX	Gain Therapeutics	Pair Corr
0.6	PHGE	Biomx Inc	Pair Corr
0.59	XFOR	X4 Pharmaceuticals	Pair Corr
0.52	OPT	Opthea Earnings Call Today	Pair Corr

The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.

The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:

How To Invest In Agios

Details

Is Agios Stock a good investment?

Details

What is Agios Pharm's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

11.64

Revenue Per Share

0.642

Quarterly Revenue Growth

0.511

Return On Assets

(0.20)

Return On Equity

0.5729

The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Agios Historical Balance Sheet

Agios Pharm Inventory

29 Million

About Agios Balance Sheet Analysis

Agios Pharm Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Agios Pharm balance sheet Correlations

Agios Pharm Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Agios Pharm balance sheet Accounts

Pair Trading with Agios Pharm

Moving against Agios Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Short Term Investments
Total Stockholder Equity	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total

Cash	- 0.99	Net Debt
Retained Earnings	- 0.85	Other Current Liab
Net Debt	- 0.81	Current Deferred Revenue
Total Liab	- 0.8	Retained Earnings
Non Current Liabilities Total	- 0.77	Retained Earnings
Other Stockholder Equity	- 0.76	Retained Earnings